Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Amoxicillin; Bismuth; Clarithromycin; Esomeprazole; Levofloxacin; Metronidazole; Potassium Citrate; Tetracycline

Criteria

Inclusion Criteria:

• Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF).

• 18-75 years old on the day of signing the ICF.

• Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.

Exclusion Criteria:

• Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases.

• Subjects or guardians refused to participate in the trial.

• Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.

• Have taken antibiotics, bismuth, proton pump inhibitors or Chinese traditional medicine 4 weeks before treatment.

• Pregnant or lactating women.

• Active peptic ulcer.

• allergic to drugs used in the trial.

• any other circumstances that are not suitable for recruitment.